BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15459547)

  • 1. Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma?
    Radny P; Bauer J; Caroli UM; Eigentler TK; Kamin A; Metzler G; Garbe C
    Dermatology; 2004; 209(3):249-50. PubMed ID: 15459547
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant interferon therapy and rheumatoid arthritis--a contraindication?
    Tsianakas A; Schiller M; Luger TA; Sunderkoetter C
    Acta Oncol; 2009; 48(3):468-9. PubMed ID: 18759142
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alopecia areata induced by interferon alpha?
    Kernland KH; Hunziker T
    Dermatology; 1999; 198(4):418-9. PubMed ID: 10490302
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 8. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
    Helbig D; Simon JC; Treudler R
    Acta Derm Venereol; 2010 May; 90(3):308-9. PubMed ID: 20526557
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary and cutaneous sarcoidosis associated with interferon therapy for melanoma.
    Pelletier F; Manzoni P; Jacoulet P; Humbert P; Aubin F
    Cutis; 2007 Nov; 80(5):441-5. PubMed ID: 18189032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant interferon therapy for melanoma.
    Hancock B; Wheatley K; Ives N; Gore M
    J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
    [No Abstract]   [Full Text] [Related]  

  • 11. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
    Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
    J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrichosis in three patients treated with interferon-alpha2.
    Kiecker F; Hofmann MA; Trefzer U
    Clin Exp Dermatol; 2009 Oct; 34(7):e414-5. PubMed ID: 19663862
    [No Abstract]   [Full Text] [Related]  

  • 13. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
    Ockenfels M; Lisch W
    Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 inhibitor induced alopecia areata.
    Guidry J; Brown M; Medina T
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 16. [Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].
    Kreutzer K; Bonnekoh B; Franke I; Ulrich J; Gollnick H
    J Dtsch Dermatol Ges; 2004 Aug; 2(8):689-94. PubMed ID: 16279234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Underutilization of anticancer agents--an example].
    Strannegård O; Thorén FB
    Lakartidningen; 2010 Dec 8-14; 107(49):3150; discussion 3150-1. PubMed ID: 21280349
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
    Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
    Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.